5 completed, 3 active not recruiting, 2 recruiting, 2 terminated. 15 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Completed 5, Active not recruiting 3, Recruiting 2, Terminated 2, Withdrawn 2, Not yet recruiting 1 |
| Phase 2 | 2 | Recruiting 1, Terminated 1 |
Follow Chikungunya Fever: new trials by email Literature Review of Chikungunya Fever trials Research Report on Chikungunya Fever
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years. DENGUE: Dengue 1,2,3,4 (attenuated) vaccine CHIKUNGUNYA: Chikungunya (CHIKV) live attenuated vaccine (VLA1555), DENGUE: Dengue 1,2,3,4 (attenuated) vaccine, Chikungunya (CHIKV) live attenuated vaccine (VLA1555) - Dengue, Chikungunya | Phase 3 | Not yet recruiting | Butantan Institute | 900 | 2027-03-31 | 2026-07-16 |
| An Efficacy, Safety, and Immunogenicity Study of CHIKV VLP Vaccine for the Prevention of Chikungunya Disease in Adolescents and Adults CHIKV VLP vaccine, Placebo - Chikungunya Virus | Phase 3 | Recruiting | Bavarian Nordic | 6144 | 2026-05-26 | 2026-06-29 |
| A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age. BBV87 Chikungunya vaccine, Placebo - Active Immunisation for Chikungunya Virus Infection | Phase 2 / Phase 3 | Recruiting | Bharat Biotech International Limited | 1000 | 2026-04-20 | 2026-04-29 |
| A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children VLA1553, Control - Chikungunya Virus Infection | Phase 3 | Withdrawn | Valneva Austria GmbH | 2026-02-06 | 2025-12-31 | |
| A Safety and Immunogenicity Study of CHIKV VLP Vaccine in Children. CHIKV VLP vaccine, Placebo - Chikungunya Virus | Phase 3 | Active not recruiting | Bavarian Nordic | 720 | 2025-06-05 | 2026-09-30 |
| A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV) VLA1553 - Chikungunya Virus Infection | Phase 3 | Withdrawn | Valneva Austria GmbH | 2024-04-10 | 2024-12-02 | |
| Long-term Follow-up Study to Evaluate Safety and Immunogenicity of CHIKV VLP Single or Booster Vaccination CHIKV VLP vaccine booster, Placebo booster - Chikungunya Virus Infection | Phase 3 | Active not recruiting | Bavarian Nordic | 715 | 2023-08-30 | 2026-08-07 |
| Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years CHIKV VLP/adjuvant, Placebo - Chikungunya Virus | Phase 3 | Completed | Bavarian Nordic | 413 | 2022-05-12 | 2024-12-13 |
| A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents Active, Placebo - Chikungunya | Phase 3 | Completed | Butantan Institute | 754 | 2022-02-14 | 2026-06-04 |
| A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine) CHIKV VLP/adjuvant, Placebo - Chikungunya Virus | Phase 3 | Completed | Bavarian Nordic | 3258 | 2021-09-29 | 2024-08-30 |
| Seamless Controlled Trial To Evaluate Safety And Immunogenicity of Chikungunya Vaccine in LatinAmerica and Asia BBV87 Chikungunya vaccine, Normal Saline - Chikungunya | Phase 2 / Phase 3 | Terminated | International Vaccine Institute | 3210 | 2021-08-01 | 2025-06-22 |
| Antibody Persistence And Long Term Safety Of A Chikungunya Virus Vaccine (VLA1553) VLA1553 - Chikungunya Virus Infection | Phase 3 | Active not recruiting | Valneva Austria GmbH | 363 | 2021-04-02 | 2026-07-09 |
| Study to Demonstrate Consistency of Three Lots of a Live-attenuated Chikungunya Virus Vaccine Candidate in Healthy Adults Biological Vaccine VLA1553 - Chikungunya Virus Infection | Phase 3 | Completed | Valneva Austria GmbH | 409 | 2021-02-22 | 2023-09-28 |
| Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults VLA1553, Placebo - Chikungunya Virus Infection | Phase 3 | Completed | Valneva Austria GmbH | 4128 | 2020-09-17 | 2023-06-28 |
| CuraChik : A Trial of the Efficacy and Safety of Chloroquine as Therapeutic Treatment of Chikungunya Disease Chloroquine - Chikungunya Virus | Phase 3 | Terminated | Assistance Publique Hopitaux De Marseille | 2006-05-01 | 2015-08-28 |
Dengue (1)
Alphavirus Infections (15) · Arbovirus Infections (15) · Infections (15) · Mosquito-Borne Diseases (15) · RNA Virus Infections (15) · Togaviridae Infections (15) · Vector Borne Diseases (15) · Virus Diseases (15) · Flaviviridae Infections (1) · Flavivirus Infections (1) · Hemorrhagic Fevers, Viral (1)
Chloroquine (1) · Exercise (1) · Saline Solution (1) · Vaccines (1) · Vaccines, Attenuated (1)
Bavarian Nordic (5) · Valneva Austria GmbH (5) · Butantan Institute (2) · Assistance Publique Hopitaux De Marseille (1) · Bharat Biotech International Limited (1) · International Vaccine Institute (1)
United States (7) · Brazil (2) · Philippines (2) · Thailand (2) · Colombia (1) · Costa Rica (1) · France (1) · Guatemala (1) · India (1) · Panama (1) · Puerto Rico (1)
Patrick Ajiboye, MD (3) · Fernanda C Boulos, MD, MSc (1) · Sushant Sahastrabuddhe, MBBS, MPH (1) · Xavier de Lamballerie, MD (1)
PMID 35709798, PMID 37321235, PMID 32220283, PMID 32497524, PMID 38294972, PMID 39004524, PMID 39116904, PMID 39146946, PMID 39243794, PMID 39255380, PMID 39998495, PMID 40158524, PMID 40158526, PMID 41380703